搜索临床试验以:抗PD-1单克隆抗体
总计7564个结果
-
Sun Yat-sen UniversityFudan University; Liaoning Tumor Hospital & Institute主动,不招人
-
Shanghai Cell Therapy Research Institute未知
-
Shanghai Cell Therapy Research Institute未知
-
Jacobio Pharmaceuticals Co., Ltd.Merck Sharp & Dohme LLC招聘中
-
Coherus Biosciences, Inc.Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.主动,不招人
-
The First Hospital of Jilin University完全的
-
Peking University Cancer Hospital & Institute招聘中
-
Beijing YouAn HospitalBeijing Gene Key Life Technology Co., Ltd.招聘中
-
Second Affiliated Hospital of Soochow University尚未招聘
-
Peking University First HospitalYiZhou International Cancer Hospital未知免疫疗法 | 质子治疗
-
Themis Bioscience GmbHAssign Data Management and Biostatistics GmbH; Optimapharm撤销
-
Peking University Cancer Hospital & Institute主动,不招人
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou Anjie Biomedical Technology Co., Ltd.完全的
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Incyte Corporation招聘中
-
Second Affiliated Hospital, School of Medicine,...招聘中
-
Shanghai Zhongshan HospitalZhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy... 和其他合作者招聘中
-
University Hospital, Bordeaux招聘中在使用 PD1/PDL1 ICIs + VEGFR-酪氨酸激酶抑制剂治疗 12 个月时有客观反应的 mRCC 患者中只有一个不良预后因素的 IMDC 良好或中等风险的治疗暂停与治疗继续 (SPICI)转移性肾细胞癌 | 每个 IMDC 评分的良好或只有一个不良预后因素中等风险法国
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.尚未招聘
-
Second Affiliated Hospital, School of Medicine,...招聘中
-
Vestre Viken Hospital TrustOslo University Hospital; University Hospital of North Norway; Helse Stavanger HF; Haukeland University... 和其他合作者招聘中
-
The First Affiliated Hospital of Zhengzhou University招聘中
-
Hangzhou Hanx Biopharmaceuticals, Ltd.Wuhan Hanxiong Bioscience, Ltd.主动,不招人